Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gd-DOTAMA
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gd-DOTAMA is a gadolinium chelate, specifically a monoamide derivative of Gd-DOTA (gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). It is primarily investigated as a magnetic resonance imaging (MRI) contrast agent. Its mechanism of action involves the paramagnetic properties of the gadolinium ion, which enhances the signal in MRI scans by affecting the relaxation times of water protons. Research has explored its potential for targeted delivery, for example, by conjugating it with vectors like glutamine to specifically target tumor cells for improved diagnostic capabilities in magnetic resonance-molecular imaging (MRMI).
- Other names
- Gd-DOTA monoamide derivative
Beyond the preview
Go deeper on Gd-DOTAMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gd-DOTAMA.